research Allergic contact dermatitis from dyes in wigs following diphencyprone treatment
Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.
Search
for
Sort by
Research
990-1000 / 1000+ results 
research 41247 Baseline distribution of eyebrow and eyelash loss by severity of scalp hair loss in phase 3 trials of baricitinib for alopecia areata
The document's conclusion cannot be provided because the content is not available.
research Analysis of Skin, Hair and Nail Diseases in the Adults with Beta Thalassemia Major
Adults with Beta Thalassemia Major are more likely to have skin, hair, and nail disorders.
research Crisaborole as a Potential Treatment for Pediatric Alopecia Areata: A Case Report and Literature Review
Crisaborole may help regrow hair in children with alopecia areata.
research A Case of Cronkhite-Canada Syndrome Involving the Entire Gastrointestinal Tract
Prednisolone and Bactrim improved symptoms in a woman with Cronkhite-Canada syndrome.
research The Efficacy of Intralesional Pentoxifylline Injection versus the Standard Intralesional Corticosteroid Injection in The Treatment of Alopecia Areata
Combining pentoxifylline with corticosteroids improves alopecia areata treatment.
research Efficacy and Safety of Combination of Mometasone Furoate 0.1% Cream and Adapalene 0.1% Gel in Alopecia Areata
The treatment is effective for mild alopecia areata but often causes mild side effects.
research Phase I-II trial of weekly bicalutamide in men with high PSA and negative biopsy
Weekly bicalutamide is safe and effective, with 50 mg/week recommended.
research Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
research Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
Patients with certain baseline characteristics are more likely to benefit early from baricitinib for alopecia areata.